Literature DB >> 19394441

Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis.

Sakib K Khalid1, Jill Lane, Victor Navarro, Guadalupe Garcia-Tsao.   

Abstract

BACKGROUND & AIMS: Over-the-counter analgesics have been proposed to lead to decompensation of compensated cirrhosis or to further decompensation of an already decompensated patient. We performed a prospective, case-control study to investigate the effects of analgesics on acute hepatic decompensation.
METHODS: Data from consecutive cirrhotic patients hospitalized at 2 tertiary care hospitals for decompensation of cirrhosis (cases, n = 91) were compared with that from consecutive patients with compensated cirrhosis that were followed in the liver clinic (n = 153) and with randomly selected noncirrhotic patients concurrently hospitalized with the cases (n = 89). All patients were given a structured questionnaire to collect information on recent use of acetaminophen, nonsteroidal anti-inflammatory drugs and alcohol.
RESULTS: Only 32 (35%) of the cirrhotic patients used over-the-counter analgesics (19% acetaminophen, 16% nonsteroidal anti-inflammatory drugs), compared with 80 of the cirrhotic controls (52%; 25% acetaminophen, 31% nonsteroidal anti-inflammatory drugs), and 62 (70%) of the noncirrhotic controls. Acetaminophen use did not differ between groups, even for those with recent alcohol use. The doses and days of nonsteroidal anti-inflammatory drug use were higher among cirrhotic patients, compared with controls. Alcohol ingestion was significantly greater among patients with alcoholic cirrhosis, compared with controls.
CONCLUSIONS: In patients with cirrhosis, acetaminophen use at doses lower than those recommended is not associated with acute hepatic decompensation, even in patients with recent alcohol ingestion. Nonsteroidal anti-inflammatory drugs might be associated with deleterious effects on cirrhosis. Alcohol ingestion is associated with decompensation in patients with alcoholic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394441      PMCID: PMC3777825          DOI: 10.1016/j.cgh.2009.04.015

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

Review 1.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Authors:  Gennaro D'Amico; Guadalupe Garcia-Tsao; Luigi Pagliaro
Journal:  J Hepatol       Date:  2005-11-09       Impact factor: 25.083

2.  Anti-inflammatory drugs and variceal bleeding: a case-control study.

Authors:  V De Lédinghen; D Heresbach; O Fourdan; P Bernard; M P Liebaert-Bories; J B Nousbaum; A Gourlaouen; M C Becker; D Ribard; P Ingrand; C Silvain; M Beauchant
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

3.  Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.

Authors:  Joan Clària; Jeffrey D Kent; Marta López-Parra; Ginés Escolar; Luís Ruiz-Del-Arbol; Pere Ginès; Wladimiro Jiménez; Boris Vucelic; Vicente Arroyo
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

Review 4.  Hepatotoxicity of analgesics and anti-inflammatory agents.

Authors:  S W Fry; L B Seeff
Journal:  Gastroenterol Clin North Am       Date:  1995-12       Impact factor: 3.806

5.  Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.

Authors:  Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis.

Authors:  F Wong; D Massie; P Hsu; F Dudley
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

8.  Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study.

Authors:  Zvi Ackerman; Fabio Cominelli; Telfer B Reynolds
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

9.  Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease.

Authors:  J L Carson; B L Strom; A Duff; A Gupta; K Das
Journal:  Arch Intern Med       Date:  1993-06-14

Review 10.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

View more
  14 in total

1.  Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Authors:  Eric S Orman; Paul H Hayashi
Journal:  J Natl Cancer Inst       Date:  2013-04-16       Impact factor: 13.506

2.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

3.  Understanding paracetamol-induced liver failure.

Authors:  Fin Stolze Larsen; Julia Wendon
Journal:  Intensive Care Med       Date:  2014-04-16       Impact factor: 17.440

Review 4.  Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Authors:  Kelly L Hayward; Elizabeth E Powell; Katharine M Irvine; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

Review 5.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

7.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

8.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

9.  Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis.

Authors:  Cristina Ripoll; Khurram Bari; Guadalupe Garcia-Tsao
Journal:  J Clin Gastroenterol       Date:  2015-08       Impact factor: 3.062

10.  Prescribing medications in patients with decompensated liver cirrhosis.

Authors:  Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.